Product Revenue, Net was Rhythm Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $194.77M of $189.76M (103%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Product Revenue, Net | — | $77.43M | $130.13M | $194.77M | |
| Product Revenue | $16.88M | — | — | — | |
| License Revenue | $6.75M | — | — | -$5.01M | |
| Total | $23.64M | $77.43M | $130.13M | $189.76M |
Rhythm Pharmaceuticals brought in $189.76M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Rhythm Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $130.13M. Product Revenue, Net was the largest at $194.77M (102.6%).
Rhythm Pharmaceuticals began breaking out Product Revenue, Net in fiscal 2023, when it brought in $77.43M. Rhythm Pharmaceuticals stopped reporting Product Revenue as a separate line after fiscal 2022, when it brought in $16.88M. The total is net of License Revenue, which took $5.01M off revenue in fiscal 2025.
Us was Rhythm Pharmaceuticals’s largest region in fiscal 2024, bringing in $96.11M of $130.13M (74%).
| Geography | FY 2021 | FY 2023 | FY 2024 |
|---|---|---|---|
| Us | — | $62.43M | $96.11M |
| United States | $3.15M | — | — |
| International | — | $15.00M | $34.02M |
| Total | $3.15M | $77.43M | $130.13M |
Rhythm Pharmaceuticals brought in $130.13M from its two regions in fiscal 2024, the year ended December 31, 2024. That was up 68.1% from $77.43M in fiscal 2023. Us was the largest at $96.11M (73.9%), ahead of International at $34.02M (26.1%).
Compared with fiscal 2023, International grew 126.7% to $34.02M and Us grew 54.0% to $96.11M.
Rhythm Pharmaceuticals began breaking out Us in fiscal 2023 and International in fiscal 2023. Rhythm Pharmaceuticals stopped reporting United States as a separate region after fiscal 2021, when it brought in $3.15M.
Rhythm Pharmaceuticals (RYTM) reports its revenue by product and service and by geography. In fiscal 2025, Product Revenue, Net was its largest product and service line, bringing in $194.77M (102.6% of the total).
Product Revenue, Net was Rhythm Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $194.77M, or 102.6% of the $189.76M total across its two product and service lines.
Us was Rhythm Pharmaceuticals' largest region in fiscal 2024, bringing in $96.11M, or 73.9% of the $130.13M total across its two regions.
International grew faster than Us in fiscal 2024, up 126.7% from $15.00M to $34.02M. Us grew 54.0% to $96.11M.
Every figure comes from Rhythm Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Rhythm Pharmaceuticals gives it, and years follow its fiscal calendar.
Rhythm Pharmaceuticals' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.